1. Home
  2. IRTC vs LQDA Comparison

IRTC vs LQDA Comparison

Compare IRTC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRhythm Technologies Inc.

IRTC

iRhythm Technologies Inc.

HOLD

Current Price

$121.92

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$43.74

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRTC
LQDA
Founded
2006
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.8B
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
IRTC
LQDA
Price
$121.92
$43.74
Analyst Decision
Strong Buy
Buy
Analyst Count
16
8
Target Price
★ $171.33
$54.38
AVG Volume (30 Days)
416.0K
★ 5.2M
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.71
51.81
EPS
N/A
★ 1.26
Revenue
★ $747,138,000.00
$158,320,000.00
Revenue This Year
$19.35
$357.27
Revenue Next Year
$16.58
$1.34
P/E Ratio
★ N/A
$33.88
Revenue Growth
26.24
★ 1031.18
52 Week Low
$100.70
$22.05
52 Week High
$210.01
$93.61

Technical Indicators

Market Signals
Indicator
IRTC
LQDA
Relative Strength Index (RSI) 66.89 50.31
Support Level $113.82 $35.00
Resistance Level $125.38 $46.67
Average True Range (ATR) 3.99 2.98
MACD 1.98 2.63
Stochastic Oscillator 95.44 93.07

Price Performance

Historical Comparison
IRTC
LQDA

About IRTC iRhythm Technologies Inc.

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: